Table 3 Comparisons of oncological outcomes according to location of previously reported 102 LGMS cases and the present case

 CDF

35/48 (72.9%)

15/23 (65.2%)

14/18 (77.8%)

64/89 (71.9%)

 NED

11/48 (22.9%)

5/23 (21.7%)

3/18 (16.7%)

19/89 (21.4%)

 AWD

0/48 (0%)

1/23 (4.4%)

0/18 (0%)

1/89 (1.1%)

 DOD

2/48 (4.2%)

2/23 (8.7%)

1/18 (5.5%)

5/89 (5.6%)

 Yes

13/49 (26.5%)

6/22 (27.3%)

5/19 (26.3%)

24/90 (26.7%)

 No

36/49 (73.5%)

16/22 (72.7%)

14/19 (73.7%)

66/90 (73.3%)

 Yes

1/49 (2.0%)

2/23 (8.7%)

1/19 (5.3%)

4/91 (4.4%)

 No

48/49 (98.0%)

21/23 (91.3%)

18/19 (94.7%)

87/91 (95.6%)